Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 12/2021

01-12-2021 | Systemic Therapy | Original Article – Cancer Research

Can axillary surgery be omitted in patients with breast pathologic complete response after neoadjuvant systemic therapy for breast cancer? A real-world retrospective study in China

Authors: Rui Chen, Shuo Li, Yan Li, Qiannan Zhu, Xiaoqing Shi, Lu Xu, Yinggang Xu, Weiwei Zhang, Xiaofeng Huang, Jue Wang, Xiaoming Zha

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2021

Login to get access

Abstract

Purpose

Studies show that axillary surgery can be potentially omitted in certain breast cancer patients who achieve breast pathologic complete response (pCR) after neoadjuvant systemic therapy (NST). However, potential differences between the ypT0 and ypTis subgroups remain to be explored. Furthermore, whether axillary surgery can be omitted in patients with clinically assessed positive axillary lymph nodes (cN+) remains unknown. This study was to evaluate the status of axillary lymph nodes for patients who achieved breast pCR after NST in the real-world study.

Methods

This retrospective cohort study included 258 patients with early or locally advanced breast cancer who underwent breast and axillary surgery after NST. Clinical and pathologic data were compared between patients with breast pCR (ypT0/is) and those without breast pCR.

Results

The rate of breast pCR after NST was 27.1% (70/258). Among the patients with initial cN0, the rate of axillary pCR was similar between the breast pCR and breast non-pCR groups (100% vs. 85.7%, P = 0.1543). Among those with breast pCR, the rate of axillary pCR was 100% in both the ypT0 and ypTis subgroups. Furthermore, among those with initial cN+, the rate of axillary pCR was higher in the breast pCR group than in the breast non-pCR group (82.7% vs. 22.9%, P < 0.0001). Among the patients with breast pCR, the rate of axillary pCR was higher in the ypT0 subgroup than in the ypTis subgroup (94.3% vs. 58.8%, P = 0.0034).

Conclusion

Axillary surgery may potentially be omitted in patients with initial cN0 who achieve breast pCR (ypT0/is), and may also be considered for omission in patients with initial cN+ who achieve ypT0 (not ypTis).
Literature
go back to reference Amiei S, van Nijnatten TJA, de Munck L, Keymeulen KBMI, Simons JM, Kooreman LFS et al (2020) Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg 271:574–580CrossRef Amiei S, van Nijnatten TJA, de Munck L, Keymeulen KBMI, Simons JM, Kooreman LFS et al (2020) Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg 271:574–580CrossRef
go back to reference Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC (2018) Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg 153:1120–1126CrossRef Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC (2018) Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg 153:1120–1126CrossRef
go back to reference Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310:1455–1461CrossRef Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310:1455–1461CrossRef
go back to reference Choi HJ, Ryu JM, Kim I, Gil-Gil M, Perez-Montero H, Fernandez-Montolí E et al (2019) Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Breast Cancer Res Treat 176:591–596CrossRef Choi HJ, Ryu JM, Kim I, Gil-Gil M, Perez-Montero H, Fernandez-Montolí E et al (2019) Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Breast Cancer Res Treat 176:591–596CrossRef
go back to reference Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H et al (2018) Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. J Natl Cancer Inst 110:628–637CrossRef Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H et al (2018) Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. J Natl Cancer Inst 110:628–637CrossRef
go back to reference Heil J, Kummel S, Schaefgen B, Paepke S, Thomssen C, Rauch G et al (2015) Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. Br J Cancer 113:1565–1570CrossRef Heil J, Kummel S, Schaefgen B, Paepke S, Thomssen C, Rauch G et al (2015) Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. Br J Cancer 113:1565–1570CrossRef
go back to reference Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU et al (2005) Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23:9304–9311CrossRef Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU et al (2005) Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23:9304–9311CrossRef
go back to reference Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E (2012) Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 48:3342–3354CrossRef Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E (2012) Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 48:3342–3354CrossRef
go back to reference Kolberg HC, Kühn T, Krajewska M, Bauerfeind I, Fehm TN, Fleige B et al (2020) Residual axillary burden after neoadjuvant chemotherapy (NACT) in early breast cancer in patients with a priori clinically occult nodal metastases—a transSENTINA analysis. Geburtshilfe Frauenheilkd 80(12):1229–1236CrossRef Kolberg HC, Kühn T, Krajewska M, Bauerfeind I, Fehm TN, Fleige B et al (2020) Residual axillary burden after neoadjuvant chemotherapy (NACT) in early breast cancer in patients with a priori clinically occult nodal metastases—a transSENTINA analysis. Geburtshilfe Frauenheilkd 80(12):1229–1236CrossRef
go back to reference Kong X, Moran MS, Zhang N, Haffty B, Yang Q (2011) Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 47:2084–2090CrossRef Kong X, Moran MS, Zhang N, Haffty B, Yang Q (2011) Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 47:2084–2090CrossRef
go back to reference Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927–933CrossRef Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927–933CrossRef
go back to reference Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14:609–618CrossRef Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14:609–618CrossRef
go back to reference Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM et al (2018) A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg 267:946–951CrossRef Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM et al (2018) A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg 267:946–951CrossRef
go back to reference Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM et al (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 98:599–609CrossRef Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM et al (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 98:599–609CrossRef
go back to reference Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF et al (2016) Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol 2:508–516CrossRef Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF et al (2016) Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol 2:508–516CrossRef
go back to reference Shen J, Gilcrease MZ, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW et al (2007) Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 109:1255–1263CrossRef Shen J, Gilcrease MZ, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW et al (2007) Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 109:1255–1263CrossRef
go back to reference Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V et al (2017) Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg 152:665–670CrossRef Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V et al (2017) Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg 152:665–670CrossRef
go back to reference von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804CrossRef von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804CrossRef
Metadata
Title
Can axillary surgery be omitted in patients with breast pathologic complete response after neoadjuvant systemic therapy for breast cancer? A real-world retrospective study in China
Authors
Rui Chen
Shuo Li
Yan Li
Qiannan Zhu
Xiaoqing Shi
Lu Xu
Yinggang Xu
Weiwei Zhang
Xiaofeng Huang
Jue Wang
Xiaoming Zha
Publication date
01-12-2021
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 12/2021
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-021-03763-8

Other articles of this Issue 12/2021

Journal of Cancer Research and Clinical Oncology 12/2021 Go to the issue

Original Article – Clinical Oncology

Traits of cancer patients and CAM usage

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine